In evidenza

Documento congiunto di SIBIOC, della Società Italiana dell’Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS), dellaSezione Italiana della European Ligand Assay Society (ELAS), e della Associazione Medici Endocrinologi (AME)[]

Revisione e aggiornamento del documento di consenso SIBioC per la ricerca e quantificazione della proteina di Bence Jones[]

Variability of cardiac troponin levels in normal subjects and in patients with cardiovascular diseases: analytical considerations and clinical relevance. A consensus document by the Study Group on Cardiac Biomarkers from Italian Society of Biochemical Chemistry (SIBioC) and European Ligand Assay Society (ELAS)[]

Big data e intelligenza artificiale in medicina di laboratorio
Artificial intelligence and big data in laboratory medicine[]

Impact on laboratory medicine of transitioning from COVID-19 pandemic to “tripledemic”[]

Saliva: Challenges, possibilities, and limits of the diagnostic use Part 2 – Pre-analytical and analytical aspects[]

High-sensitivity Point of Care Testing (POCT) methods for Cardiac Troponins: analytical features and clinical relevance.
A consensus document by the Study Group on Cardiac Biomarkers from the Italian Society of Biochemical Chemistry (SIBioC) and the European Ligand Assay Society (ELAS)[]

Il monitoraggio terapeutico della Cannabis medica nei pazienti pediatrici: l’esperienza dell’Istituto Giannina Gaslini
Therapeutic Drug Monitoring of medical Cannabis in pediatrics: the experience of Giannina Gaslini Institute[]

Generative Artificial Intelligence in (laboratory) medicine: friend or foe?[]

Il premio Nobel per la Medicina 2023: la svolta delle terapie a RNA[]